



ASX ANNOUNCEMENT

26 June 2025

TREASURY UPDATE

Opyl Limited ("**OPL**" or "the **Company**"), a technology company transforming the drug discovery and trial process through AI-driven solutions, is pleased to announce the following update.

In line with the Strategic Review Announcement on 10 June 2025, the Company has further enhanced its digital innovation credentials by taking a step towards building a strategic holding of crypto currency. We believe this move strengthens our treasury diversification and reflects our commitment to aligning shareholder value creation with a disciplined, forward-looking capital allocation framework.

OPL has executed the purchase of ~2 Bitcoin for ~\$330,000. OPL purchased the Bitcoin via ASX listed Exchange Traded Fund ("**ETF**") DigitalX Bitcoin ETF (BTXX:ASX).

The move underscores our proactive approach to diversifying our treasury assets, aligning our balance sheet with emerging digital asset trends and enabling future opportunities through AI infrastructure.

Crypto Currency Expertise – Tony G:

The Company is fortunate to benefit from the strategic advisory insights of Non-Executive Director Antanas Guoga ("Tony G"). Tony G is a renowned entrepreneur with deep roots in the crypto space. With a successful track record in early-stage digital asset investments, Tony G has been instrumental in nurturing and scaling transformative crypto ventures. Notably, Tony G is the top shareholder and chairman of SOL Strategies (CSE:HODL) —a Canadian listed company with a market capitalisation of CAD\$375M that is known for its pioneering initiatives in the blockchain space. Tony is a key thought-leader, capable of bridging conventional finance with breakthrough digital innovation.



Funding Facility

Tony G has agreed to provide access to up to \$2 Million through a non-dilutive finance facility to support OPL's growth objectives. The facility will have an initial term of 2 years, incur interest at 6.5% per annum and be secured against OPL's Bitcoin holdings. It may be repaid early at any time by OPL without penalty. The facility is provided on commercial, arm's length terms. The facility is also subject to early termination by Tony G in the event of a default, such as non-payment or breach of facility terms. The facility provides the capital flexibility OPL requires to seize growth opportunities, invest in strategic initiatives, and scale operations with confidence.

Forward-Looking Strategy:

This announcement reaffirms our dedication to technological leadership in the pharmaceutical industry. The sector is starting to leverage advancements in blockchain, AI, and distributed ledger systems. Decentralised clinical trials have the potential to connect researchers, institutions, and patients across geographies, which enhances transparency, accelerates innovation, and fosters patient-centric care. Utilising decentralised solutions can not only streamline the path from lab to clinic but can also build resilience into healthcare systems, ensuring that critical insights and treatment protocols are accessible and secure across a globally integrated network.

Antanas Guoga ("Tony G"), Director of OPL, commented:

"Our acquisition of ~2 BTC represents a decisive step towards broadening our digital asset portfolio. I understand that some shareholders might not yet be familiar with Bitcoin or the broader cryptocurrency market. However, I urge our investors to take the time to fully understand these digital assets. With increasing endorsement by institutions and governments worldwide, Bitcoin and other cryptocurrencies are emerging as a validated and forward-looking asset class."

This announcement has been authorised for release by the Board

-ENDS-



For investor enquiries:

Saurabh Jain

saurabh@trialkey.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.